Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Sep 23

PMID 36139573

Authors

Isaku Okamoto

Takuro Okada

Kunihiko Tokashiki

Kiyoaki Tsukahara

Affiliations

Soon will be listed here.

Abstract

Head and neck photoimmunotherapy (HN-PIT), a new treatment developed for local control of head and neck carcinoma, uses cetuximab sarotalocan sodium with a laser system to specifically destroy only tumor cells. No studies have examined the impact of HN-PIT on the quality of life (QOL) of patients with head and neck cancer. This study assessed the QOL of patients with unresectable locally advanced or locally recurrent head and neck carcinoma (LA/LR-HNC) treated with HN-PIT. Nine eligible patients with unresectable LA/LR-HNC who underwent HN-PIT at our institution between 20 January 2021 and 30 April 2022 were included in the study. They completed a QOL evaluation form. The primary endpoint was QOL assessment. The secondary endpoints were overall response rate, overall survival (OS), progression-free survival, and adverse events. QOL was compared before and 4 weeks after HN-PIT. There were no significant changes in all QOL assessment parameters after treatment with HN-PIT. The overall response rate was 89%, and safety was acceptable. For patients with unresectable LA/LR-HNC, HN-PIT provided good local control without decreasing the QOL. The addition of HN-PIT to conventional head and neck carcinoma treatment may lead to the prolongation of OS in head and neck carcinoma.

Citing Articles

Predictive Factors for the Efficacy of Head and Neck Photoimmunotherapy and Optimization of Treatment Schedules.

Nishikawa D, Shimabukuro T, Suzuki H, Beppu S, Terada H, Kobayashi Y Cancer Diagn Progn. 2025; 5(2):179-188.

PMID: 40034957 PMC: 11871859. DOI: 10.21873/cdp.10428.

Near Infrared Photoimmunotherapy for Locoregionally Recurrent Oropharyngeal Squamous Cell Carcinoma at Tongue Base After Chemoradiotherapy: A Case Report and Literature Review.

Tamagawa S, Okuda K, Nishikawa D, Kono M, Hotomi M Cureus. 2024; 16(11):e74742.

PMID: 39735016 PMC: 11682689. DOI: 10.7759/cureus.74742.

Antitumor host immunity enhanced by near-infrared photoimmunotherapy.

Fukushima H, Furusawa A, Okada R, Fujii Y, Choyke P, Kobayashi H Cancer Sci. 2024; 116(3):572-580.

PMID: 39663860 PMC: 11875768. DOI: 10.1111/cas.16427.

The Latest Treatment for Head and Neck Cancers: Transoral Robotic Surgery and Photoimmunotherapy.

Matsumoto F Juntendo Iji Zasshi. 2024; 69(2):97-102.

PMID: 38854451 PMC: 11153055. DOI: 10.14789/jmj.JMJ22-0038-R.

Lemierre's Syndrome after Head and Neck Photoimmunotherapy for Local Recurrence of Nasopharyngeal Carcinoma.

Nishimura M, Okamoto I, Ito T, Tokashiki K, Tsukahara K Case Rep Oncol. 2024; 17(1):180-185.

PMID: 38304554 PMC: 10834035. DOI: 10.1159/000535597.

References

Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen A, Razavi D, Maher E . Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol. 1994; 33(8):879-85. DOI: 10.3109/02841869409098450. View

Okamoto I, Okada T, Tokashiki K, Tsukahara K . Photoimmunotherapy for Managing Recurrent Laryngeal Cancer Cervical Lesions: A Case Report. Case Rep Oncol. 2022; 15(1):34-39. PMC: 8832182. DOI: 10.1159/000521435. View

Okamoto I, Okada T, Tokashiki K, Tsukahara K . A Case Treated With Photoimmunotherapy Under a Navigation System for Recurrent Lesions of the Lateral Pterygoid Muscle. In Vivo. 2022; 36(2):1035-1040. PMC: 8931901. DOI: 10.21873/invivo.12799. View

Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T . Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers (Basel). 2020; 12(11). PMC: 7699139. DOI: 10.3390/cancers12113427. View

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

Matsuki T, Okamoto I, Fushimi C, Sawabe M, Kawakita D, Sato H . Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Med. 2020; 9(14):5015-5024. PMC: 7367642. DOI: 10.1002/cam4.3124. View

Tahara M, Okano S, Enokida T, Ueda Y, Fujisawa T, Shinozaki T . A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. Int J Clin Oncol. 2021; 26(10):1812-1821. PMC: 8449763. DOI: 10.1007/s10147-021-01960-6. View

Okamoto I, Sato H, Kondo T, Koyama N, Fushimi C, Okada T . Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study. Acta Otolaryngol. 2019; 139(10):918-925. DOI: 10.1080/00016489.2019.1648867. View

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

10.

Nagaya T, Friedman J, Maruoka Y, Ogata F, Okuyama S, Clavijo P . Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. Cancer Immunol Res. 2019; 7(3):401-413. PMC: 8237708. DOI: 10.1158/2326-6066.CIR-18-0546. View

11.

Nishikawa D, Suzuki H, Koide Y, Beppu S, Kadowaki S, Sone M . Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab. Cancers (Basel). 2018; 10(12). PMC: 6316608. DOI: 10.3390/cancers10120466. View

12.

Ogawa M, Tomita Y, Nakamura Y, Lee M, Lee S, Tomita S . Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget. 2017; 8(6):10425-10436. PMC: 5354669. DOI: 10.18632/oncotarget.14425. View

13.

Ueki Y, Takahashi T, Ota H, Shodo R, Yamazaki K, Horii A . Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. Eur Arch Otorhinolaryngol. 2020; 277(8):2341-2347. DOI: 10.1007/s00405-020-05945-5. View

14.

Okamoto I, Tsukahara K, Sato H . Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. Sci Rep. 2022; 12(1):2025. PMC: 8821556. DOI: 10.1038/s41598-022-06084-z. View

15.

Matsuo M, Yasumatsu R, Masuda M, Toh S, Wakasaki T, Hashimoto K . Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol. 2019; 101:104525. DOI: 10.1016/j.oraloncology.2019.104525. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

18.

Minohara K, Matoba T, Kawakita D, Takano G, Oguri K, Murashima A . Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. Sci Rep. 2021; 11(1):16992. PMC: 8379150. DOI: 10.1038/s41598-021-96538-7. View

19.

Cognetti D, Johnson J, Curry J, Kochuparambil S, McDonald D, Mott F . Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021; 43(12):3875-3887. PMC: 9293150. DOI: 10.1002/hed.26885. View

20.

Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K . Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. Sci Rep. 2021; 11(1):2741. PMC: 7854616. DOI: 10.1038/s41598-021-82448-1. View